Illumina (NASDAQ:ILMN) SVP Nicholas Naclerio sold 2,000 shares of the company’s stock on the open market in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $133.56, for a total transaction of $267,120.00. Following the completion of the transaction, the senior vice president now directly owns 23,146 shares in the company, valued at approximately $3,091,380. Illumina, Inc. (NASDAQ:ILMN) shares after opening at $145.91 moved to $149.43 on last trade day and at the end of the day closed at $147.98. Company price to sales ratio in past twelve months was calculated as 13.37 and price to cash ratio as 16.30. Illumina, Inc. (NASDAQ:ILMN) showed a positive weekly performance of 12.16%.
Biogen Idec (NASDAQ:BIIB) EVP Steven H. Holtzman unloaded 1,221 shares of the company’s stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $291.00, for a total value of $355,311.00. Following the completion of the sale, the executive vice president now directly owns 6,970 shares of the company’s stock, valued at approximately $2,028,270. Biogen Idec Inc. (NASDAQ:BIIB) shares advanced 2.76% in last trading session and ended the day on $306.20. BIIB return on equity ratio is recorded as 23.30% and its return on assets is 16.90%. Biogen Idec Inc. (NASDAQ:BIIB) yearly performance is 42.29%.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Director Rick Winningham unloaded 27,500 shares of Jazz Pharmaceuticals plc stock on the open market in a transaction dated Thursday, April 17th. The shares were sold at an average price of $140.00, for a total transaction of $3,850,000.00. Following the completion of the sale, the director now directly owns 13,587 shares in the company, valued at approximately $1,902,180. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares moved up 5.07% in last trading session and was closed at $145.35, while trading in range of $140.00 – $149.47. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) year to date (YTD) performance is 14.85%.
Vical (NASDAQ:VICL) VP Lawrence Russell Smith sold 1,912 shares of the company’s stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $1.21, for a total value of $2,313.52. Following the completion of the sale, the vice president now directly owns 193,213 shares in the company, valued at approximately $233,788. Vical Incorporated (NASDAQ:VICL) weekly performance is 13.39%. On last trading day company shares ended up $1.27. Vical Incorporated (NASDAQ:VICL) distance from 50-day simple moving average (SMA50) is -7.16%. Analysts mean target price for the company is $3.23.
Leave a Reply